Company / Operating Income
Corbus Pharmaceuticals Holdings, Inc. Operating Income History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$56.0M
FY2022
5-year range
-$122.8M / -$32.6M
FY2018-FY2022
Trend
+54.4%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income returned to growth in FY2022 after 4 years of decline, reaching -$56M.
Based on SEC 10-K filings.
-$56M in FY2022.
Improved from -$77M to -$56M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating income increased 54.4% year-over-year.
- Peak operating income was recorded in FY2015.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$56.0M | +54.4% |
| FY2021 | -$122.8M | -59.3% |
| FY2020 | -$77.1M | -35.9% |
| FY2019 | -$56.7M | -74.3% |
| FY2018 | -$32.6M | -267.8% |
| FY2017 | -$8.9M | +0.0% |
| FY2016 | -$8.9M | -234.5% |
| FY2015 | -$2.6M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026